Aarey Drugs & Pharmaceuticals Ltd Company Summary

Aarey Drugs & Pharmaceuticals Ltd was originally incorporated on May 15, 1990 as a private limited company in Mumbai with the name Niharika Textiles & Chemicals Pvt Ltd. The company was originally promoted by Prakash Mandhana, Kavita Mandhana and Neeta Mandhana. In March, 1993, the Aarey Group of companies belonging to Ghatalia family took over the company and the company was converted into public limited company. Also, the name of the company was changed from Niharika Textiles & Chemicals Pvt Ltd to Aarey Drugs & Pharmaceuticals Ltd.The Company is one of the manufacturer and suppliers of pharmaceutical raw materials, Chemicals, Pharmaceuticals ingredients, APIs Drugs, Food Colours and Flavours. The company is engaged in the business of manufacturing, selling of drugs & pharmaceutical products and is governed by a number of central and state legislations that regulate the business. Apart from the bulk drug manufacturing activity, they also undertake importing & distributing of various industrial chemicals & solvents throughout the country. The company has their manufacturing unit located at Thane.The companys products include Methyl Nitro Imidazole, Metronidazole & Metronidazole Benzoate. Their pharmaceutical products are sourced from the authentic vendors to assure the quality and effectiveness. The pharmaceutical products offered by the company are in compliance with IP/ BP/ CP/ USP standards. They have their registered office is located at Thane and their corporate office is located at Mumbai.The company was established with the main object setting up manufacturing facilities for Bulk Drugs. In the year 1993, the company came with a public issue of 27,50,000 equity shares of Rs 10 each for cash at par aggregating to Rs 275 lakh. Also, the company shares were listed on the BSE, ASE & DSE.In May 2009, the company plant started to upgrade the existing plant into international standards.In June 2016, the Company commenced manufacturing of Mono Methyl Urea & Di Methyl Urea. In 2017-18, it added new products i.e. Erithromycin Derivates & Mafenamic Acid with capacity of 10 m.t. & 25 m.t. respectively in June 2017. In 2018-19, it commenced manufacturing of products i.e. Ortho Para Nitro Anisole, 2-Bromomethyl-1,3 dioxolane, and Mefenamic Acid. It also commenced manufacturing products i.e.Metformin & Urasil.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.

Aarey Drugs & Pharmaceuticals Ltd Company Summary

ATTENTION INVESTORS

Risk Disclosure on Derivatives

We are ISO 27001:2013 Certified.

MARKET

IDEAS

MUTUAL FUNDS

TRADING DOCUMENTATION

CALCULATOR

GLOSSARY (A-Z)

ATTENTION INVESTORS

Risk Disclosure on Derivatives

We are ISO 27001:2013 Certified.